2017 CVM News: Dr. Brian VanderVen's paper pinpoints a  new target for tuberculosis drugs

Office of Marketing and Communications. Media Relations

dc.contributor.author	Office of Marketing and Communications. Media Relations
dc.date.accessioned	2017-07-11T17:38:12Z
dc.date.available	2017-07-11T17:38:12Z
dc.date.issued	2017-06-27
dc.identifier.uri	https://hdl.handle.net/1813/52037
dc.description.abstract	The news item from the Cornell Chronicle is about: Dr. Brian VanderVen, assistant professor of microbiology and immunology, and colleagues at Cornell’s College of Veterinary Medicine, have discovered a key metabolic mechanism in Mycobacterium tuberculosis (Mtb) bacteria, which presents as a novel drug target for potentially treating tuberculosis. The finding is published in the journal eLife.
dc.language.iso	en_US
dc.publisher	Cornell University, College of Veterinary Medicine
dc.subject	Cornell University. College of Veterinary Medicine -- Periodicals.
dc.subject	VanderVen, Brian
dc.subject	Roberts, Lauren Cahoon
dc.subject	Cornell Chronicle
dc.title	2017 CVM News: Dr. Brian VanderVen's paper pinpoints a new target for tuberculosis drugs
dc.title.alternative	New discovery holds potential as tuberculosis drug
dc.type	article